Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) announced that its first quarter 2014 financial results will be released after the market closes on Monday, May 12, 2014. Following the release, Aerie will host a live conference call and webcast at 5:00 p.m. Eastern Time to discuss the company’s financial results and provide a general business update. Aerie Pharmaceuticals Inc (NASDAQ:AERI) shares after opening at $15.01 moved to $15.98 on last trade day and at the end of the day closed at $15.83.Company price to cash ratio as 5.30. Aerie Pharmaceuticals Inc (NASDAQ:AERI) showed a positive weekly performance of 4.01%.
Yesterday’s announcement that Pfizer is seeking to buy AstraZeneca Plc (AZN) in a new $100 billion megamerger is putting the industry on notice that a company that was once the world’s biggest drugmaker is seeking to quickly reclaim its title. A consummated deal would generate more than $75 billion in combined yearly revenue, based on current sales. It may also offer new growth opportunities and tax advantages for Pfizer, and reopen a door on a promising family of cancer medications. AstraZeneca plc (ADR) (NYSE:AZN) shares advanced 12.16% in last trading session and ended the day on $77.01. AZN return on equity ratio is recorded as 19.10% and its return on assets is 8.10%. AstraZeneca plc (ADR) (NYSE:AZN) yearly performance is 56.40%.
GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH) a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced that the United States Food and Drug Administration (FDA) has granted Fast Track designation to Sativex® for the treatment of pain in patients with advanced cancer, who experience inadequate analgesia during optimized chronic opioid therapy. Sativex is currently in Phase 3 clinical trials for this indication. GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH) shares moved up 5.02% in last trading session and was closed at $65.24, while trading in range of $61.48-$69.00. GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH) year to date performance is 57.05%.
Johnson & Johnson (NYSE:JNJ)‘s stock had its “neutral” rating reaffirmed by JPMorgan Chase & Co. in a research note issued on Thursday. They currently have a $51.00 price objective on the stock, down from their previous price objective of $52.00. JPMorgan Chase & Co.’s price objective would indicate a potential downside of 49.67% from the company’s current price. Johnson & Johnson (NYSE:JNJ) weekly performance is 1.34%. On last trading day company shares ended up $101.34. Johnson & Johnson (NYSE:JNJ) distance from 50-day simple moving average is 6.31%. Analysts mean target price for the company is $104.55.